Luminist Capital’s Quest Diagnostics DGX Stock Holding History

Luminist Capital’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-189	Closed	-$32.8K	–	138
2025 Q4	$32.8K	Hold	189	–	–	0.04%	91
2025 Q3	$34.4K	Hold	189	–	–	0.03%	130
2025 Q2	$33.9K	Hold	189	–	–	0.03%	107
2025 Q1	$32K	Hold	189	–	–	0.03%	87
2024 Q4	$28.5K	Buy	+189	New	+$29.4K	0.05%	85

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Luminist Capital's DGX Position: Q1 2026 in Review

Luminist Capital sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 189 shares — an estimated $32.8K sold.

Luminist Capital first reported a position in DGX in Q4 2024 and held it in 5 quarters. The position peaked at $34.4K in Q3 2025. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Luminist Capital reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
Luminist Capital sold 189 Quest Diagnostics shares in Q1 2026, an estimated $32.8K.
Luminist Capital first reported a position in Quest Diagnostics in Q4 2024 and held it in 5 quarters.
Luminist Capital's Quest Diagnostics position peaked at $34.4K in Q3 2025.
1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Luminist Capital's 13F filing for Q1 2026, filed 24 Apr 2026.